The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 1081-1087

  Krönke, Gerhard ^a,b   Reich, Nicole ^a   Scholtysek, Carina ^a,b   Akhmetshina, Alfiya ^a   Uderhardt, Stefan ^a,b   Zerr, Pawel ^a   Palumbo, Katrin ^a   Lang, Veronika ^a   Dees, Clara ^a   Distler, Oliver ^c   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; BLEOMYCIN; COLLAGEN TYPE 1; ICOSANOID; LIPOXIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST; SKIN FIBROSIS; TISSUE REACTION; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; BLEOMYCIN; CELLS, CULTURED; DERMIS; EICOSANOIDS; FIBROBLASTS; FIBROSIS; LIPOXINS; MESODERM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84860917443     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200745     Document Type: Article

References (27)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Abraham DJ, Krieg T, Distler J, et al. Overview of pathogenesis of systemic sclerosis. Rheumatology 2009;48:iii3-7.
3. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005;6:1191-7. (Pubitemid 43045627)
4. Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001;2:612-9. (Pubitemid 32677628)
5. Kühn H, O'Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 2006;45:334-56. (Pubitemid 43818131)
6. Börgeson E, Docherty NG, Murphy M, et al. Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB J 2011;25:2967-79.
7. Ryan A, Godson C. Lipoxins: regulators of resolution. Curr Opin Pharmacol 2010;10:166-72.
8. Kowal-Bielecka O, Kowal K, Distler O, et al. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease-insights and potential therapeutic implications. Nat Clin Pract Rheumatol 2007;3:43-51.
9. Kowal-Bielecka O, Kowal K, Distler O, et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and anti-inflammatory lipid mediators. Arthritis Rheum 2005;52:3783-91. (Pubitemid 41798216)
10. Sun D, Funk CD. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J Biol Chem 1996;271:24055-62. (Pubitemid 26327385)
11. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22. (Pubitemid 351948641)
12. Palumbo K, Zerr P, Tomcik M, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011;70:1320-6.
13. Marquart S, Zerr P, Akhmetshina A, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010;62:3467-76.
14. Avouac J, Fürnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT4 prevents inflammation-driven fibrosis in systemic sclerosis animal models. Arthritis Rheum 2011;63:800-9.
15. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961-72.
16. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011;63:1396-404.
17. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60:1129-36.
18. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
19. Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008;58:1475-84. (Pubitemid 351705937)
20. Krönke G, Bochkov VN, Huber J, et al. Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J Biol Chem 2003;278:51006-14. (Pubitemid 38020334)
21. Wu SH, Lu C, Dong L, et al. Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int 2005;68:35-46. (Pubitemid 43181362)
22. Bian XW, Jiang XF, Chen JH, et al. Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas. Int Immunopharmacol 2006;6:90-9.
23. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62:2831-44.
24. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008;49:103-13. (Pubitemid 350298736)
25. Ihn H, Yamane K, Tamaki K. Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J Invest Dermatol 2005;125:247-55. (Pubitemid 41648157)
26. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011;6:509-37.
27. Martins V, Valença SS, Farias-Filho FA, et al. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol 2009;182:5374-81.